Last reviewed · How we verify

NCT06956703: NAZA

NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study

Recruiting now Last updated 29 May 2025
What this trial tests

trial in Gastro-Intestinal Disorder in 240 participants. Currently enrolling.

Timeline
12 December 2022
Primary endpoint
28 February 2027
28 February 2027

Quick facts

Lead sponsorUniversity of Nottingham
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment240
Start date12 December 2022
Primary completion28 February 2027
Estimated completion28 February 2027
Sites1 location across United Kingdom

Conditions studied

Sponsor

University of Nottingham

Who can join

16 and older, any sex, with Gastro-Intestinal Disorder or Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants. The main question it aims to answer is: Are there differences in inflammatory markers between IBD and non-IBD (control) participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastro-Intestinal Disorder

Currently open trials in the same condition.

Other University of Nottingham trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06956703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing